EpiPen competitor the Auvi-Q is coming back on the market, its manufacturer said Wednesday. Auvi-Q was removed from the market last year because of manufacturing problems. Spencer Williamson, Kaleo’s president and chief executive, says Kaleo will offer Auvi-Q at an affordable price even to patients without health insurance, and promises that competition will benefit patients. Kaleo’s announcement comes as Mylan has been under fire for the price of its EpiPen product, which is used to counteract life-threatening anaphylactic reactions.